Kamada Ltd.
KMDAHealthcare|Drug Manufacturers - Specialty & Generic|IL
$7.23
+0.36 (+5.24%)
DCF Value
$35.01
Tangible Book / Share
$2.51
Graham Number
$6.35
Cash / Share
$1.21
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06958796 Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) | Cytomegalovirus, Organ Transplant | P4 | Recruiting | 80 | RCT, Open-label | Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months |
| NCT07009548 CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients | Cytomegalovirus (CMV) Infection | P4 | By Invite | 45 | Open-label | Cytogam |
| NCT02956122 A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD | Graft Versus Host Disease | P2P3 | Terminated | 1 | RCT, Double-blind | GLASSIA, methylprednisolone or equivalent steroid, Albumin |
| NCT00460096 Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency | Alpha 1-Antitrypsin Deficiency | P2P3 | Completed | 50 | RCT, Double-blind | Kamada-API |
| NCT04204252 Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" | Alpha 1-Antitrypsin Deficiency | P3 | Terminated | 98 | RCT, Double-blind | Alpha 1-Antitrypsin, Placebo |
| NCT02040090 Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects | Rabies | P2P3 | Completed | 118 | RCT, Double-blind | Active rabies vaccine (US-FDA approved) |
| NCT01217671 International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema | Emphysema | P2P3 | Completed | 168 | RCT, Double-blind | Kamada AAT for inhalation |
| NCT02912845 Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies | Rabies | P3 | Completed | 30 | Open-label | KamRAB - HRIG |
| NCT02005848 Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes | New Onset Type-1 Diabetes | P2 | Completed | 70 | RCT, Double-blind | Alpha-1 Antitrypsin |
| NCT01661192 Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes | Type 1 Diabetes, Beta Cell Preservation | P2 | Completed | 12 | Open-label | AAT( Alpha 1 Antitrypsin) |
| NCT00499837 Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients | Cystic Fibrosis | P2 | Completed | 21 | RCT, Double-blind | Aerosolized, human, plasma-derived Alpha-1 Antitrypsin |
| NCT01304537 Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus | Type 1 Diabetes Mellitus | P1P2 | Completed | 24 | RCT, Open-label | Alpha-1 Antitrypsin 40mg (AAT, Glassia®), Alpha-1 Antitrypsin 60mg (AAT, Glassia®), Alpha-1 Antitrypsin 80mg (AAT, Glassia®) |
| NCT04550325 Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 | Covid19, Pneumonia, Viral | P1P2 | Completed | 12 | Open-label | Kamada Anti-SARS-CoV-2 |
| NCT02614872 Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation | Transplantation, Lung Rejection | P2 | Completed | 30 | RCT, Open-label | GLASSIA® and Institution standard of care (SOC) |
| NCT02001688 Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" | Alpha-1 Antitrypsin Deficiency | P2 | Completed | 36 | RCT, Double-blind | Kamada-AAT for Inhalation, 80mg, Placebo, Kamada-AAT for Inhalation, 160mg |
| NCT03172455 Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) | Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease | NO_LONGER_AVAILABLE | — | — | Glassia |